Prescription for Better Access podcast

Charting a Path Forward for More Patient-Centered Value Assessment Methods

0:00
NaN:NaN:NaN
Rewind 15 seconds
Fast Forward 15 seconds

In this episode, we talk with Richard Xie, Senior Health Economist at RA Capital, and Gunnar Esiason, Senior Director of Patient Engagement at Raven (RA Capital Ventures), about value frameworks in pharma. We unpack how Generalized Cost-Effectiveness Analysis (GCEA) builds on traditional Cost-Effectiveness Analysis (CEA) and differs from ICER’s model. The conversation explores what these approaches mean for pricing, access, and patient voice—especially in rare and high-innovation settings.

Through the Cidara CD388 flu drug case, we discuss how assumptions shape value and trade-offs from manufacturer and patient perspectives. The episode highlights how evidence, incentives, and outcomes align—or conflict—in today’s system, and what reforms could better connect value frameworks to affordability and equitable access.

Questions or comments? Email [email protected].

Follow us on X, LinkedIn, YouTube, and Threads.

More episodes from "Prescription for Better Access"